{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:26:21Z","timestamp":1760189181058},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/bor.0b013e328346f7fb","type":"journal-article","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T07:08:52Z","timestamp":1303283332000},"page":"346-351","source":"Crossref","is-referenced-by-count":15,"title":["New treatment targets in ankylosing spondylitis and other spondyloarthritides"],"prefix":"10.1097","volume":"23","author":[{"given":"In-Ho","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2003.019174","article-title":"Six months open label trial of leflunomide in active ankylosing spondylitis","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/art.22060","article-title":"Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis","volume":"54","author":"Appel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.59.2.135","article-title":"Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis: cellularity correlates with the degree of enhancement detected by magnetic resonance imaging","volume":"59","author":"Bollow","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780370709","article-title":"Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients","volume":"37","author":"Braun","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar2035","article-title":"Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis","volume":"8","author":"Appel","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/rheumatology\/ken362","article-title":"The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B","volume":"47","author":"Rodriguez-Escalera","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R17-6-20210128","first-page":"626","article-title":"Improvement of refractory ankylosing spondylitis in response to rituximab: a case report","volume":"67","author":"Schleenbecker","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"R18-6-20210128","first-page":"626","article-title":"Lack of efficacy of rituximab in spondyloarthropathies: data of 8 patients prospectively followed in the French AIR (Auto-Immunity and Rituximab) registry.","volume":"68","author":"Nocturne","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jbspin.2008.01.023","article-title":"Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"issue":"Suppl 2","key":"R20-6-20210128","first-page":"317","article-title":"Successful treatment of neutrophilic granulomatous dermatitis with rituximab in a patient with rheumatoid arthritis and spondylitis ankylosans: a case report","volume":"67","author":"Toussaint","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/art.23266","article-title":"Spondylarthritis in the absence of B lymphocytes","volume":"58","author":"Baeten","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"Van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"R27-6-20210128","first-page":"826","article-title":"Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus","volume":"35","author":"Lindholm","year":"2008","journal-title":"J Rheumatol"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.079095","article-title":"Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response","volume":"67","author":"Jonsdottir","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.21344","article-title":"Life threatening steroid-resistant autoimmune anemia successfully treated with rituximab: a case report.","volume":"84","author":"Noel","year":"2009","journal-title":"Am J Hematol"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","article-title":"Rituximab is effective in the treatment of refractory Churg\u2013Strauss syndrome and is associated with diminished T-cell interleukin-5 production","volume":"47","author":"Pepper","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R33-6-20210128","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations","volume":"35","author":"Seo","year":"2008","journal-title":"J Rheumatol"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"issue":"Suppl","key":"R35-6-20210128","first-page":"S818","article-title":"Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions","volume":"62","author":"Mease","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/rheumatology\/keg230","article-title":"Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis","volume":"42","author":"Zou","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard.2004.024455","article-title":"Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis","volume":"64","author":"Zou","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/ard.2008.097030","article-title":"Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition","volume":"68","author":"Olivieri","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"R40-6-20210128","first-page":"623","article-title":"Abatacept for therapy of spondyloarthritis due to therapy failure or contraindications of TNF-alpha antagonists","volume":"68","author":"Berner","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R41-6-20210128","first-page":"1132","article-title":"Treatment of axial spondyloarthritis (SpA) refractory to anti-TNFalpha with CTLA-4-Ig (abatacept): results of an open-label pilot study","volume":"76","author":"Compaore","year":"2009","journal-title":"Rev Rhumatisme"},{"issue":"Suppl 3","key":"R42-6-20210128","first-page":"60","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open label 24-week study","volume":"69","author":"Song","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R43-6-20210128","first-page":"939","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.","volume":"63","author":"Mease","year":"2011","journal-title":""},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.192.5.681","article-title":"Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells","volume":"192","author":"Abrams","year":"2000","journal-title":"J Exp Med"},{"key":"R45-6-20210128","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2005.037465","article-title":"Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases","volume":"65","author":"Francois","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R46-6-20210128","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratacos","year":"1994","journal-title":"Br J Rheumatol"},{"key":"R47-6-20210128","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.53.6.425-b","article-title":"Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis","volume":"53","author":"Tutuncu","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"R48-6-20210128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/rheumatology\/36.3.400","article-title":"A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies","volume":"36","author":"Claudepierre","year":"1997","journal-title":"Br J Rheumatol"},{"key":"R49-6-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002960050066","article-title":"In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility","volume":"18","author":"Falkenbach","year":"1998","journal-title":"Rheumatol Int"},{"key":"R50-6-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","article-title":"Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis","volume":"26","author":"Bal","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R51-6-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jbspin.2010.08.004","article-title":"Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists","volume":"77","author":"Brulhart","year":"2010","journal-title":"Joint Bone Spine"},{"key":"R52-6-20210128","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1136\/ard.2009.126706","article-title":"Mixed response to tocilizumab for ankylosing spondylitis","volume":"69","author":"Henes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R54-6-20210128","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.24899","article-title":"Successful treatment of reactive arthritis with a humanized antiinterleukin-6 receptor antibody, tocilizumab","volume":"61","author":"Tanaka","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R56-6-20210128","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and effector functions of T(H)17 cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"key":"R57-6-20210128","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"R58-6-20210128","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"key":"R59-6-20210128","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R60-6-20210128","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/art.27622","article-title":"Role of Th17 cells in human autoimmune arthritis","volume":"62","author":"Leipe","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R61-6-20210128","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"R62-6-20210128","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3748\/wjg.15.5784","article-title":"Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease","volume":"15","author":"Liu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R63-6-20210128","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","article-title":"Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis","volume":"74","author":"Wendling","year":"2007","journal-title":"Joint Bone Spine"},{"key":"R64-6-20210128","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R65-6-20210128","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00296-009-0883-x","article-title":"Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis","volume":"29","author":"Wang","year":"2009","journal-title":"Rheumatol Int"},{"key":"R66-6-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis.","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"Suppl","key":"R67-6-20210128","first-page":"S351","article-title":"In situ detection of IL-17 secreting cells in the bone marrow of facet joints obtained from patients with ankylosing spondylitis","volume":"58","author":"Appel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R68-6-20210128","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"R69-6-20210128","first-page":"3840","article-title":"The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis","volume":"62","author":"Baeten","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R70-6-20210128","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol"},{"issue":"Suppl 3","key":"R71-6-20210128","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1111\/j.1872-034X.2007.00249.x","article-title":"Roles of the novel interleukin-12-associated cytokine, interleukin-23, in the regulation of T-cell-mediated immunity","volume":"37","author":"Matsui","year":"2007","journal-title":"Hepatol Res"},{"issue":"Suppl 3","key":"R72-6-20210128","first-page":"104","article-title":"In situ analysis of IL-23 secreting cells in the spine of patients with ankylosing spondylitis","volume":"69","author":"Appel","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R73-6-20210128","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet"},{"key":"R74-6-20210128","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1136\/ard.2007.080283","article-title":"The IL23R Arg381Gln nonsynonymous polymorphism confers susceptibility to ankylosing spondylitis","volume":"67","author":"Rueda","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R75-6-20210128","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.23389","article-title":"Association of interleukin-23 receptor variants with ankylosing spondylitis","volume":"58","author":"Rahman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R76-6-20210128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/ken501","article-title":"Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series","volume":"48","author":"Karaderi","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R77-6-20210128","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"R78-6-20210128","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R79-6-20210128","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R80-6-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2010.01.030","article-title":"Efficacy and safety of ABT-874, a monoclonal antiinterleukin 12\/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation\/retreatment and 60-week open-label extension phases of a randomized phase II trial","volume":"64","author":"Kimball","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R81-6-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"R82-6-20210128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"R83-6-20210128","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Antiinterleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R84-6-20210128","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e328346f7fb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:01:33Z","timestamp":1620946893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201107000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328346f7fb","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}